The bill amends the Federal Food, Drug, and Cosmetic Act to require that every dietary supplement marketed in the United States be listed with the Food and Drug Administration by the responsible person named on the label (or the U.S. agent for foreign entities). Listings must include label copy, ingredient lists and amounts, claims, contact information, container sizes, directions, warnings, allergen statements, product form, and a digital label; FDA will assign a product listing number.
The measure directs FDA to create a publicly searchable electronic database within two years (excluding specified confidential fields), sets deadlines for initial listings and updates, adds misbranding and a new prohibited act tied to debarred persons, and authorizes modest appropriations to stand up the program. For industry, the bill creates new data-reporting obligations and compliance timelines; for regulators and clinicians, it aims to centralize product information to support recalls, surveillance, and consumer inquiries.
At a Glance
What It Does
The bill requires the manufacturer, packer, or distributor whose name appears on the label (or its U.S. agent) to submit a standardized listing for each dietary supplement to FDA. The Secretary assigns a product listing number, may require electronic submission, and must publish most listing fields in a searchable online database within two years.
Who It Affects
Domestic responsible persons (manufacturers, packers, distributors) and foreign firms that operate through U.S. agents, plus the retail supply chain and FDA as the implementing agency. Clinical toxicologists, poison control centers, and public-health investigators will also use the database.
Why It Matters
This is a statutory move from a largely market-notification regime toward centralized disclosure: it standardizes label and ingredient reporting and creates a public registry that can speed recalls and adverse-event follow-up. It also creates compliance deadlines, record requests, and enforcement hooks (misbranding and a new prohibited act) that change operational and legal risk for firms.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The core of the bill inserts a new section (403D) into the FD&C Act making listing mandatory for every dietary supplement sold in the U.S. The person whose name appears on the label (the responsible person) must submit a listing that mirrors label content: product names and identity, brand/flavor variants, full label copy as an electronic file, serving size and servings per container, directions, warnings, allergen statements, and the product form (tablet, capsule, gummy, etc.). The bill ties the obligation to the label’s responsible person and, for foreign entities, to a designated U.S. agent.
Ingredient reporting is explicit and granular: the listing must include every ingredient that is required to appear on the supplement facts panel under current CFR rules, plus the amount per serving of each listed dietary ingredient. The bill requires reporting of amounts within proprietary blends, but instructs FDA not to disclose those proprietary blend amounts in the public database.
The statute cross-references existing labeling regulations (21 C.F.R. parts 101.4 and 101.36) so the submission aligns with today’s label content rather than creating a divergent set of labeling standards.Timing and change-management are key compliance hooks. Products already in interstate commerce by January 1, 2027 must be listed within 18 months after enactment; new products must be listed at the time of introduction.
Responsible persons must notify FDA within one year after they discontinue marketing a product, and they must update listing information within 30 days after introducing a product bearing a changed label. FDA may require electronic formats and must acknowledge whether a submission is complete or explain why it is incomplete.Administrative mechanics: FDA must assign a dietary supplement product listing number (which can cover identical formulations or minor variants) and establish a publicly searchable database within two years.
That database will contain most listing fields but exclude certain contact and proprietary-blend quantity information; those excluded fields are designated to be withheld under FOIA exemptions. FDA can also require additional supplier, facility, or holding-location details on 10-calendar-day notice.
The bill authorizes appropriations to hire personnel and run the program for fiscal years 2026–2030.Enforcement and statutory adjustments: the bill amends the misbranding provision to make failure to file a required listing, required change, or requested additional information a misbranding violation. It also adds a new prohibited act that blocks the introduction of supplements prepared, packed, or held with the assistance of, or at the direction of, a person debarred under section 306.
Finally, a rule-of-construction clause clarifies that the listing requirement does not create premarket approval authority for FDA.
The Five Things You Need to Know
Existing dietary supplements marketed on or before January 1, 2027 must be listed within 18 months after enactment; supplements introduced after that date must be listed at the time they enter interstate commerce.
FDA must build a publicly searchable electronic database within two years of enactment, but the database will not publish U.S. agent contact details, certain business addresses, or proprietary-blend quantities.
A responsible person must submit changes that appear on a product label within 30 days of first introducing the changed product into interstate commerce, and must notify FDA within one year after discontinuing a product.
On FDA request, a responsible person has 10 calendar days to provide full business names and physical and mailing addresses for all manufacturing, packaging, labeling, holding locations, and ingredient sources.
Failure to file required listings or updates is treated as misbranding, and the bill also makes it unlawful to introduce products prepared or held with the assistance of a person debarred under section 306.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
States that the act may be cited as the "Dietary Supplement Listing Act of 2026." This is a standard naming provision with no operational effect, but it frames the bill's purpose for regulatory and appropriation language.
Universal listing requirement
Creates the new statutory duty: every dietary supplement marketed in the United States must be listed with FDA. The obligation is tied to the 'responsible person' named on the product label; for foreign entities, the U.S. agent assumes listing responsibilities. By anchoring duties to label identity, the statute creates a clear compliance entity rather than diffusing responsibility across contract manufacturers or retailers.
Specified listing fields and reliance on current labeling regs
Lists the exact fields required in each submission: product name(s), statement of identity, brand and flavor variants, responsible-person contact and U.S. agent information, an electronic label copy, ingredient lists consistent with 21 C.F.R. §§101.4 and 101.36, amounts per serving (including proprietary-blend amounts), servings per container, directions, warnings, allergen statements, product form, and any label claims governed by section 403(r). The cross-reference to existing CFR labeling rules avoids inadvertently rewriting label-content standards but compels firms to transmit the same information to FDA in machine-readable form.
Submission flexibility, grouping, and timing
Permits a single listing submission to cover multiple SKUs that share identical formulations or differ only by color, excipient, or flavoring; FDA will issue a product listing number that may cover multiple package sizes. The statute sets staggered timing: an 18-month compliance window for products on the market by Jan 1, 2027, immediate listing for new introductions, a one-year window to notify FDA after discontinuation, and a 30-day deadline to submit label-driven changes once the product bearing the change is introduced into interstate commerce.
Supplemental information, product numbers, and database
Authorizes FDA to request supplier and facility-level addresses and requires the responsible person to comply within 10 calendar days. FDA must provide product listing numbers and create a public, searchable electronic database within two years, while withholding certain contact and proprietary information from public disclosure. FDA also may require electronic formats and must notify submitters whether listings are complete or deficient upon receipt, establishing an administrative workflow for compliance tracking.
Confidentiality limitations and funding
Limits how the database and requests interact with other disclosure laws: it clarifies that the statute does not expand FDA’s inspection authority, does not permit disclosure prohibited by other statutes (e.g., 301(j) and 1905), and prevents public release of locations not identified on the label or proprietary-blend quantities. The bill also authorizes specific appropriations for startup and operating costs for FY2026–2030, providing a finite funding stream tied to implementation.
New misbranding provision and prohibited act
Adds a misbranding ground: failing to file a required listing, required change, or requested information under 403D constitutes misbranding under section 403(z). It also creates a new prohibited act in section 301(jjj) banning the introduction of a dietary supplement prepared, packed, or held with the assistance or direction of a person debarred under section 306. Together these amendments provide legal mechanisms for enforcement beyond civil information remedies.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Consumers and patients — They gain easier public access to standardized label information and ingredient amounts via a searchable registry, which can speed recall notices and support informed purchasing decisions.
- FDA and public-health investigators — A centralized, machine-readable inventory of marketed products will streamline surveillance, adverse-event correlation, and trace-back during outbreaks or contamination events.
- Clinicians, poison control centers, and laboratories — Ready access to label and ingredient data reduces time to identify exposures, interpret laboratory results, and advise treatment.
- Retailers and healthcare purchasers — A public database reduces information-gathering costs when vetting product claims, ingredients, and supplier contacts, improving supply-chain transparency.
Who Bears the Cost
- Responsible persons (manufacturers/packers/distributors) — They must create, submit, and maintain detailed electronic listings and respond to FDA requests under tight deadlines, increasing compliance workload and potential legal exposure.
- Foreign firms and their U.S. agents — Companies outside the U.S. must designate and equip U.S. agents to meet listing and response obligations, creating new contractual and logistical costs.
- Small supplement companies — Smaller firms face disproportionate administrative burdens and potential expense to generate electronic label files, maintain accurate ingredient records, and hire compliance support.
- FDA — Implementing and vetting a searchable database, processing submissions, and enforcing new misbranding and prohibited-act provisions requires staff, IT resources, and ongoing funding despite the bill’s appropriations.
Key Issues
The Core Tension
The central dilemma is balancing the public health value of a comprehensive, searchable registry against protecting commercially sensitive formulation data and avoiding disproportionate compliance costs: the bill expands transparency and traceability but forces regulators to decide how much proprietary information to shield, how rigorously to verify submissions, and whether the government has the operational capacity to police accuracy without imposing heavy burdens on small or foreign firms.
The bill forces a trade-off between transparency and protection of proprietary information. It requires granular ingredient reporting while simultaneously instructing FDA not to publish proprietary-blend quantities; but that carve-out shifts the burden to FDA and courts to police what truly qualifies as proprietary and to determine whether other submitted fields indirectly reveal sensitive formulation data.
The statutory FOIA withholding references are narrow and rely on cross-references to other exemptions, creating potential dispute over which fields remain shielded in practice.
Operationally, the statute creates real verification and enforcement questions. FDA receives a single submission claiming completeness and then merely notifies submitters whether a filing is complete or deficient; the agency still needs resources and protocols to test accuracy, reconcile listings with actual products on the market, and decide when inaccuracies rise to misbranding enforcement.
Short response windows (10 days for supplier/facility info, 30 days for label changes) are administrable for larger firms but may be burdensome for small businesses or foreign supply chains, creating potential gaps in accuracy and compliance. Finally, the ability to group multiple variants under one listing and to reserve listing numbers reduces friction but may enable minimal or strategic filings that mask substantial product differences.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.